PALB2 and breast carcinoma: Estimating these while accounting for competing risks (non-breast cancer related death) yielded 4.6%, 4.9% and 3.2% lower estimates for lifetime risks in carriers of the PALB2 and CHEK2 mutations, and women with high PRS, respectively (Supplementary Figs. 1–3 and Supplementary Table 3).